# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's...
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Insti...
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First P...
Piper Sandler analyst Biren Amin initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Overweight rating and anno...
Oppenheimer analyst Mark Breidenbach maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price ta...
HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price t...